Review

polyclonal rabbit anti ifitm1 antibody (Cell Signaling Technology Inc)

Cell Signaling Technology Inc is a verified supplier

Cell Signaling Technology Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cell Signaling Technology Inc polyclonal rabbit anti ifitm1 antibody
Polyclonal Rabbit Anti Ifitm1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/polyclonal+rabbit+anti-ifitm1+antibody/IFITM1+Antibody/pmc12272759-22-0-7
Average 94 stars, based on 41 article reviews

polyclonal rabbit anti ifitm1 antibody - by Bioz Stars, 2026-10

94/100 stars

Images

other:

Article Title: USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy.
Article Snippet: The anti-LC3-II (1:1000) (#3868, Cell Signaling technology, Danvers, MA, USA), anti-ULK1 (1:1000) (#8054, Cell Signaling technology, Danvers, MA, USA), anti-p62 (1:1000) (GTX100685, Genetex, Alton Pkwy Irvine, CA, USA), anti- Phospho-ULK1 (1:1000) (Ser555) (#5869, Cell Signaling technology, Danvers, MA, USA), anti-USP24 (1:1000) (13126- 1-AP, Proteintech, Rosemont, IL, USA), anti-E2F4 (1:1000) (ab150360, Abcam, Cambridge, MA, USA), anti-E2F1 (1:1000) (#3742, Cell Signaling technology, Danvers, MA, USA), anti-γ-H2AX (1:1000) (AP0099, Abclonal, China), anti-CCNB1 (1:200) (sc-245, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-TRAF6 (1:1000) (#8028, Cell Signaling technology, Danvers, MA, USA), anti-ATG3 (1:1000) (#3415, Cell Signaling technology, Danvers, MA, USA), anti-ATG4B (1:1000) (GTX115678, Genetex, Alton Pkwy Irvine, CA, USA), anti-ATG5 (1:1000) (#12994, Cell Signaling technology, Danvers, MA, USA), anti-ATG7 (1:1000) (#8558, Cell Signaling technology, Danvers, MA, USA), anti-ATG12 (#4180, Cell Signaling technology, Danvers, MA, USA), anti-ATG16L1 (1:1000) (#8089, Cell Signaling technology, Danvers, MA, USA), anti-mTOR (1:1000) (#ab2732, Abcam, Cambridge, MA, USA), anti-pmTOR(S2448) (1:1000) (ab109268, Abcam, Cambridge, MA, USA), antiBeclin-1 (1:1000) (#3495, Cell Signaling technology, Danvers, MA, USA), anti-ABCG2 (1:1000) (#42078, Cell Signaling technology, Danvers, MA, USA), anti-PD-L1 (1:1000) (GTX104763, Genetex, Alton Pkwy Irvine, CA, USA), and anti-actin (1:3000) (GTX26276, Genetex, Alton Pkwy Irvine, CA, USA) were used as the first antibodies.

Article Title: SARS-CoV-2 Omicron Envelope T9I adaptation confers resistance to autophagy
Article Snippet: Primary antibodies used in this study: Polyclonal rabbit anti-StrepII (1:2000; Abcam, #ab76949), monoclonal mouse anti-V5 (1:3000; Cell Signalling, #80076), monoclonal mouse anti-VSV-M (1:5000; Kerafast, #EB0011), polyclonal rabbit anti-LC3 (1:200; Sigma-Aldrich, #L8918), monoclonal mouse anti-p62 (1:1000; Abcam, ab56416), polyclonal rabbit anti-IFITM1 (1:500; Cell Signaling, #13126), polyclonal rabbit anti-IFITM2 (1:500; Abcam, #ab236735), monoclonal rabbit anti-IFITM3 (1:500; Cell Signaling, #59212), monoclonal rat anti-GAPDH (1:1000; Biolegend, #607902) and monoclonal mouse anti-β-actin (1:10,000; Sigma-Aldrich, #A5441).

Article Title: Alternative splicing expands the antiviral IFITM repertoire in Chinese rufous horseshoe bats
Article Snippet: The following antibodies and dilutions were used: mouse anti-FLAG-M2 (Sigma; 1:20,000), mouse anti-IFITM1 (Proteintech; 1:50,000), rabbit anti-IFITM2 (Cell Signalling Technology; 1:1,000), rabbit anti-fragilis (Abcam; 1:5,000), mouse anti-beta-actin (Santa Cruz Biotechnology; 1:1,000), rabbit anti-alpha-tubulin (Proteintech; 1:10,000), mouse anti-GAPDH (Proteintech; 1:1,000), IRDye 800CW goat anti-mouse (LICOR; 10,000), IRDye 800CW goat anti-rabbit (LICOR; 1:10,000), HRP-conjugated goat anti-rabbit IgG (Abcam; 10,000), HRP-conjugated goat anti-mouse IgG (Abcam; 10,000).

Article Title: USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy.
Article Snippet: The anti-USP24 (1:200) (13126-1-AP, Proteintech, USA), anti-PD-L1 (1:200) (#13684, Cell Signaling technology, Danvers, MA, USA), anti-LC3-II (1:200) (#3868, Cell Signaling technology, Danvers, MA, USA) and anti-CD3 (1:200) antibodies (A700-174, Bethyl Laboratories, Inc., Montgomery, TX, USA) were used to cover sections for 1 h at room temperature, and the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) was used for visualizing the immunoreactivity.

Western Blot:

Article Title: Mutation T9I in Envelope confers autophagy resistance to SARS-CoV-2 Omicron
Article Snippet: Polyclonal rabbit anti-ABCG2 Antibody (IP) , Cell Signaling Technology , Cat#4477S; RRID: AB 10544928. .. Polyclonal rabbit anti-IFITM1 Antibody (WB 1:500) , Cell Signaling Technology , Cat13126; RRID: AB_2798126. .. Polyclonal rabbit anti-IFITM2 Antibody (WB 1:500) , Abcam , Cat#ab236735.

Article Title: Mechanisms of mesothelial cell response to viral infections: HDAC1-3 inhibition blocks poly(I:C)-induced type I interferon response and modulates the mesenchymal/inflammatory phenotype
Article Snippet: .. The primary antibodies used for Western blotting experiments are mAb anti-E-cadherin (BD610181) from BD Transduction Laboratories (Franklin Lakes, NJ, USA). mAbs anti-Mx1 (sc-34128), anti-tubulin (sc-32293), anti-HSP90 (sc-13119) were from Santa Cruz Biotechnology (Dallas, TX, USA); Abs anti-IFIT1 (23247-1-AP), anti-Snail (L70G2), anti-STAT1 (9172), anti-phospho STAT3 (Y701), and anti-STAT3 (9132) were from Cell Signaling Technology (Danvers, MA, USA). pAb anti-IFITM1 (600-74-1) was from Proteintech (Rosemont, IL, USA). pAbs anti-MMP14 (ab53712) was from Abcam (Cambridge, UK): pAbs anti-phospho STAT1 (s727). .. HRP-conjugated secondary antibodies used were purchased from Jackson ImmunoResearch, Cambridge, UK: anti-rabbit (JI 711-036-152) and anti-mouse (JI 715-036-150).

Blocking Assay:

Article Title: Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication.
Article Snippet: For immunoblotting, HEp-2 cell monolayers were left untreated or treated with 1 μM of MEDS433, or with 100 ng/ml of IFNα for 24 or 48 h. Protein extracts were then prepared as previously described (Luganini et al., 2008), and equal amounts were fractionated by 4–15% SDS-PAGE and then transferred to PVDF membranes (BioRad). .. Filters were blocked for 2 h at 37 ◦C in EveryBlot Blocking Buffer (BioRad), and immunostained with either the mouse anti-hDHODH mAb (E− 8, Santa Cruz Biotechnology), or the rabbit anti-IFI6 pAb (54355, Cell Signaling Technology, CST), or the rabbit anti-IFITM1 pAb (13126, CST), or the rabbit anti-IRF-7 mAb (D2A1J, CST), or the rabbit anti-IRF-1 mAb (D5E4, CST), or the rabbit anti-OAS2 pAb (54155, CST), or the rabbit anti-IRF3 mAb (D6I4C, CST), or the rabbit anti-phospho IRF3 (Ser 386) (E7J8G, CST). .. A rabbit anti-vinculin mAb (E1E9V, CST) or a rabbit anti-GAPDH mAb (D16H11, CST) were used as controls for protein loading.

Image Search Results

Journal: Intractable & Rare Diseases Research

Article Title: The novel role of IFITM1-3 in myogenic differentiation of C2C12 cells

doi: 10.5582/irdr.2023.01050

Figure Lengend Snippet: Primer sequences for RT-qPCR

Article Snippet: The membranes were blocked with 5% skim milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 2 h at room temperature, and then the membranes were incubated with primary antibodies, namely, rabbit anti-desmin (ab32362, Abcam, USA), rabbit anti-MyoD (ab203383, Abcam, USA), rabbit anti-MYF5 (ab125301, Abcam, USA), rabbit anti-IFITM1 (bs-1031R, Bioss, China), rabbit anti-IFITM2 (bs-15517R, Bioss, China), mouse anti-IFITM3 (bsm-51629M, Bioss, China), and rabbit anti-GAPDH (ab8245, Abcam, USA), at 4°C overnight.

Techniques: Sequencing

Increased expression of IFITM1-3 during myogenic differentiation of C2C12 myoblasts. (A) Relative expression of Ifitm1-3 during the myogenic differentiation process. (B) Western blot evaluating the protein levels of IFITM1-3. (C) Quantification of band intensity as described above is shown. The level of proteins was normalized to that of GAPDH. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant.

Journal: Intractable & Rare Diseases Research

Article Title: The novel role of IFITM1-3 in myogenic differentiation of C2C12 cells

doi: 10.5582/irdr.2023.01050

Figure Lengend Snippet: Increased expression of IFITM1-3 during myogenic differentiation of C2C12 myoblasts. (A) Relative expression of Ifitm1-3 during the myogenic differentiation process. (B) Western blot evaluating the protein levels of IFITM1-3. (C) Quantification of band intensity as described above is shown. The level of proteins was normalized to that of GAPDH. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant.

Techniques: Expressing, Western Blot

Knockdown of Ifitm1, 2, and 3 by siRNAs blocks myogenic differentiation in C2C12 cells. (A) Microscopic images of Giemsa staining for C2C12 myoblasts on day 3 of myogenic differentiation after transfection with siRNAs targeting Ifitm1-3. Two different siRNAs were used for each targeting gene. Transfection without siRNAs, but with transfection reagent was set as mock. Magnification: 100×. (B) Percentage fusion on day 3 of myogenic induction and transfection with siRNAs as described above, calculated by dividing the number of nuclei within multinucleated myofibers by the total number of nuclei. NC represents the group without siRNAs and transfection reagents. (C) Downregulated protein expression of myogenin, MyoD, Myf5, and desmin after interference by siRNAs targeting Ifitm1-3. (D) Quantification of band intensity as described above is shown. The level of proteins was normalized to that of GAPDH. Statistical significance: *P< 0.05; **P < 0.01; ***P < 0.001; NS, not significant.

Journal: Intractable & Rare Diseases Research

Article Title: The novel role of IFITM1-3 in myogenic differentiation of C2C12 cells

doi: 10.5582/irdr.2023.01050

Figure Lengend Snippet: Knockdown of Ifitm1, 2, and 3 by siRNAs blocks myogenic differentiation in C2C12 cells. (A) Microscopic images of Giemsa staining for C2C12 myoblasts on day 3 of myogenic differentiation after transfection with siRNAs targeting Ifitm1-3. Two different siRNAs were used for each targeting gene. Transfection without siRNAs, but with transfection reagent was set as mock. Magnification: 100×. (B) Percentage fusion on day 3 of myogenic induction and transfection with siRNAs as described above, calculated by dividing the number of nuclei within multinucleated myofibers by the total number of nuclei. NC represents the group without siRNAs and transfection reagents. (C) Downregulated protein expression of myogenin, MyoD, Myf5, and desmin after interference by siRNAs targeting Ifitm1-3. (D) Quantification of band intensity as described above is shown. The level of proteins was normalized to that of GAPDH. Statistical significance: *P< 0.05; **P < 0.01; ***P < 0.001; NS, not significant.

Techniques: Staining, Transfection, Expressing

Identification and validation of IFITM1,3-interacting proteins. (A) Principle of co-immunoprecipitation and liquid chromatography combined with tandem mass spectrometry (LC-MS/MS). (B) The protein- protein interaction network if IFITM1,3 (overlapped) revealed by STRING analysis. A total of 84 unique homologous proteins are shown in the network. Three clusters are indicated in different colors. Cluster 1: muscle filament sliding (green color); Cluster 2: ribosome series proteins (red color); Cluster 3: regulation of mRNA metabolic process (blue color). Associations are represented by the lines. Thicker lines represent stronger associations. (C) Co-IP assays show the interaction between desmin and IFITM1, 3.

Journal: Intractable & Rare Diseases Research

Article Title: The novel role of IFITM1-3 in myogenic differentiation of C2C12 cells

doi: 10.5582/irdr.2023.01050

Figure Lengend Snippet: Identification and validation of IFITM1,3-interacting proteins. (A) Principle of co-immunoprecipitation and liquid chromatography combined with tandem mass spectrometry (LC-MS/MS). (B) The protein- protein interaction network if IFITM1,3 (overlapped) revealed by STRING analysis. A total of 84 unique homologous proteins are shown in the network. Three clusters are indicated in different colors. Cluster 1: muscle filament sliding (green color); Cluster 2: ribosome series proteins (red color); Cluster 3: regulation of mRNA metabolic process (blue color). Associations are represented by the lines. Thicker lines represent stronger associations. (C) Co-IP assays show the interaction between desmin and IFITM1, 3.

Techniques: Immunoprecipitation, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Co-Immunoprecipitation Assay

Overlapped interacted proteins for IFITM1 and IFITM3

Journal: Intractable & Rare Diseases Research

Article Title: The novel role of IFITM1-3 in myogenic differentiation of C2C12 cells

doi: 10.5582/irdr.2023.01050

Figure Lengend Snippet: Overlapped interacted proteins for IFITM1 and IFITM3

Techniques:

GO and KEGG pathway enrichment analysis of 84 proteins that interact with IFITM1, 3 (overlapped). (A) KEGG classification map of differentially expressed genes. The y-axis shows the metabolic pathway. (B) Biological process (BP). (C) Cellular component (CC). (D) Molecular function (MF). The x-axis represents gene ratio = count/set size. Dot size represents the number of genes, and the color bar represents the Padj-value.

Journal: Intractable & Rare Diseases Research

Article Title: The novel role of IFITM1-3 in myogenic differentiation of C2C12 cells

doi: 10.5582/irdr.2023.01050

Figure Lengend Snippet: GO and KEGG pathway enrichment analysis of 84 proteins that interact with IFITM1, 3 (overlapped). (A) KEGG classification map of differentially expressed genes. The y-axis shows the metabolic pathway. (B) Biological process (BP). (C) Cellular component (CC). (D) Molecular function (MF). The x-axis represents gene ratio = count/set size. Dot size represents the number of genes, and the color bar represents the Padj-value.

Techniques:

Upregulation of IFITMs in HTR8/SVneo cells following IFN-β treatment was evaluated by western blot and immunofluorescence IFN-β inhibits invasion of HTR8/SVneo cells (A–E) and primary human EVCTs (F–I). HTR8/SVneo cells and EVCTs were incubated for 48 h with IFN-β (10, 100, or 1000 IU/mL). (A) Cell lysates (40 μg) were loaded in 4–15% SDS-PAGE gradient gels and blots were probed for IFITM1, IFITM2/3, and vinculin expression. One representative experiment (out of 3) is shown. (B) Representative image of HTR8/SVneo cells immunostained for cytokeratin 7 (marker of trophoblast, magenta) and IFITM1 (green) or IFITM2/3 (red), and then counterstained with DAPI (blue). Scale bars: 10 μm. Inhibition of HTR8/SVneo cell invasion following IFN-β treatment , quantified using IncuCyte technology (C–E) . HTR8/SVneo cells were cultured in a monolayer in 96-well plates. Cells were treated for 48 h, then a wound was made using a 96-well wound maker; this was covered by Matrigel and cells were imaged with Incucyte every 30 min for 48 h. (C) Representative images of HTR8/SVneo cell invasion at 48 h. The blue region denotes the area of the initial wound (light blue line) covered by advancing cells. (D) Time course of wound closure expressed as relative wound density (%). Values are reported as mean ± SEM. (E) Comparison between vehicle and IFN-β-treated cells was performed using an analysis of the area under the curve of the replicates represented in (D). Values are reported as mean + SEM (n = 6 wells/condition, n = 3 experiments). Statistical analysis was performed with one-way ANOVA to compare treatment to vehicle controls. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Upregulation of IFITMs in EVCTs following IFN-β treatment was evaluated by western blot (F) and immunofluorescence (G) . (F) Cell lysates (40 μg) from isolated EVCTs were loaded in 4–15% SDS-PAGE gradient gels and blots were probed for IFITM1, IFITM2/3, and vinculin expression. One representative experiment (out of 3) is shown. (G) Representative image of isolated EVCTs and placental explants immunostained for cytokeratin 7 (marker of trophoblast, magenta) and IFITM1 (green) or IFITM2/3 (red), and then counterstained with DAPI (blue). Scale bars: 10 μm. Inhibition of EVCT invasion following IFN-β treatment using villous explant culture model (H–I) . (H) Representative image of extravillous explants cultured on Matrigel and immunostained for integrin α5 (ITGA5, marker of invasion, red). Scale bars: 100 μm. (I) Statistical analysis of the invasion distance of ITGA5 + EVCTs, as representatively shown in H. Values are presented as mean + SD (n = 3 explants per condition, n = 3 placentas). One-way ANOVA was performed to compare treatment to vehicle control; ∗∗∗∗p < 0.0001.

Journal: iScience

Article Title: IFITM1 inhibits trophoblast invasion and is induced in placentas associated with IFN-mediated pregnancy diseases

doi: 10.1016/j.isci.2023.107147

Figure Lengend Snippet: Upregulation of IFITMs in HTR8/SVneo cells following IFN-β treatment was evaluated by western blot and immunofluorescence IFN-β inhibits invasion of HTR8/SVneo cells (A–E) and primary human EVCTs (F–I). HTR8/SVneo cells and EVCTs were incubated for 48 h with IFN-β (10, 100, or 1000 IU/mL). (A) Cell lysates (40 μg) were loaded in 4–15% SDS-PAGE gradient gels and blots were probed for IFITM1, IFITM2/3, and vinculin expression. One representative experiment (out of 3) is shown. (B) Representative image of HTR8/SVneo cells immunostained for cytokeratin 7 (marker of trophoblast, magenta) and IFITM1 (green) or IFITM2/3 (red), and then counterstained with DAPI (blue). Scale bars: 10 μm. Inhibition of HTR8/SVneo cell invasion following IFN-β treatment , quantified using IncuCyte technology (C–E) . HTR8/SVneo cells were cultured in a monolayer in 96-well plates. Cells were treated for 48 h, then a wound was made using a 96-well wound maker; this was covered by Matrigel and cells were imaged with Incucyte every 30 min for 48 h. (C) Representative images of HTR8/SVneo cell invasion at 48 h. The blue region denotes the area of the initial wound (light blue line) covered by advancing cells. (D) Time course of wound closure expressed as relative wound density (%). Values are reported as mean ± SEM. (E) Comparison between vehicle and IFN-β-treated cells was performed using an analysis of the area under the curve of the replicates represented in (D). Values are reported as mean + SEM (n = 6 wells/condition, n = 3 experiments). Statistical analysis was performed with one-way ANOVA to compare treatment to vehicle controls. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Upregulation of IFITMs in EVCTs following IFN-β treatment was evaluated by western blot (F) and immunofluorescence (G) . (F) Cell lysates (40 μg) from isolated EVCTs were loaded in 4–15% SDS-PAGE gradient gels and blots were probed for IFITM1, IFITM2/3, and vinculin expression. One representative experiment (out of 3) is shown. (G) Representative image of isolated EVCTs and placental explants immunostained for cytokeratin 7 (marker of trophoblast, magenta) and IFITM1 (green) or IFITM2/3 (red), and then counterstained with DAPI (blue). Scale bars: 10 μm. Inhibition of EVCT invasion following IFN-β treatment using villous explant culture model (H–I) . (H) Representative image of extravillous explants cultured on Matrigel and immunostained for integrin α5 (ITGA5, marker of invasion, red). Scale bars: 100 μm. (I) Statistical analysis of the invasion distance of ITGA5 + EVCTs, as representatively shown in H. Values are presented as mean + SD (n = 3 explants per condition, n = 3 placentas). One-way ANOVA was performed to compare treatment to vehicle control; ∗∗∗∗p < 0.0001.

Article Snippet: Rabbit anti-IFITM1 polyclonal antibody , Sigma-Aldrich , Cat# HPA004810; RRID: AB_1851419.

Techniques: Western Blot, Immunofluorescence, Incubation, SDS Page, Expressing, Marker, Inhibition, Cell Culture, Isolation

Ectopic expression of FLAG and IFITMs in HTR8/SVneo cells transduced with IFITM1–3 was verified by western blot, immunofluorescence, and flow cytometry IFITM1 inhibits invasion of HTR8/SVneo cells (A–E) and primary human EVCTs. (A) Cell lysates (40 μg) were loaded in 4–15% SDS-PAGE gradient gels and blots were probed for IFITM1, IFITM2/3, and vinculin expression. A representative experiment is shown. (B) Representative image of transduced HTR8/SVneo cells immunostained for FLAG (yellow) and IFITM1 (green) or IFITM2/3 (red), and then counterstained with DAPI (blue). Scale bar: 10 μm. (C) HTR8/SVneo cells transduced with a vector containing IFITM1 (green), IFITM2 (orange), IFITM3 (magenta), or a control empty vector (dark blue) were stained with antibodies for IFITM1, IFITM2/3, and FLAG, as well as corresponding isotypes. Cells were then analyzed by flow cytometry. Inhibition of IFITM1-transduced HTR8/SVneo cell invasion , quantified using IncuCyte technology (D–F) . HTR8/SVneo cells transduced with IFITM1–3 were cultured in a monolayer in 96-well plates and a wound was made using a 96-well wound maker; this was covered by Matrigel and cells were imaged with Incucyte every 30 min for 48 h. (D) Representative images of transduced HTR8/SVneo cell invasion at 48 h. The blue region denotes the area of the initial wound (light blue line) covered by advancing cells. (E) Time course of wound closure expressed as relative wound density (%). Values are reported as mean ± SEM of the percentage. (F) Comparison between cells transduced with IFITM1–3 and the empty vector was performed using an analysis of the area under the curve of the replicates represented in (E). Values are represented as mean + SEM (n = 6 wells/condition, n = 3 experiments). Statistical analysis was performed with one-way ANOVA to compare treatment to vehicle controls. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Ectopic expression of GFP , FLAG , and IFITMs in EVCT explants transduced with IFITM1–3 was verified by immunofluorescence (G–J) . (G) Representative image of placental explants transduced with GFP or IFITM1–3, cultured on Matrigel, and immunostained for FLAG (yellow), GFP (green), and IFITM1 (red) or IFITM2/3 (magenta), and then counterstained with DAPI (blue). Scale bars: 100 μm. (H) Representative image of EVCT explants transduced with GFP or IFITM1–3, cultured on Matrigel, and immunostained for FLAG (yellow), GFP (green), and ITGA5 (red) or HLAG (magenta), and then counterstained with DAPI (blue). Scale bars: 100 μm. Inhibition of IFITM1-transduced EVCT invasion using villous explant culture model (I–J) . (I) Representative image of transduced extravillous explants cultured on Matrigel and immunostained for integrin α5 (ITGA5, marker of invasion, red). Scale bars: 100 μm. (J) Statistical analysis of the invasion distance of ITGA5 + EVCTs, as representatively shown in I. Values are presented as mean + SD (n = 3 explants per condition, n = 3 placentas). One-way ANOVA was performed to compare treatment to pTRIP-GFP control; ∗∗∗∗p < 0.0001.

Journal: iScience

Article Title: IFITM1 inhibits trophoblast invasion and is induced in placentas associated with IFN-mediated pregnancy diseases

doi: 10.1016/j.isci.2023.107147

Figure Lengend Snippet: Ectopic expression of FLAG and IFITMs in HTR8/SVneo cells transduced with IFITM1–3 was verified by western blot, immunofluorescence, and flow cytometry IFITM1 inhibits invasion of HTR8/SVneo cells (A–E) and primary human EVCTs. (A) Cell lysates (40 μg) were loaded in 4–15% SDS-PAGE gradient gels and blots were probed for IFITM1, IFITM2/3, and vinculin expression. A representative experiment is shown. (B) Representative image of transduced HTR8/SVneo cells immunostained for FLAG (yellow) and IFITM1 (green) or IFITM2/3 (red), and then counterstained with DAPI (blue). Scale bar: 10 μm. (C) HTR8/SVneo cells transduced with a vector containing IFITM1 (green), IFITM2 (orange), IFITM3 (magenta), or a control empty vector (dark blue) were stained with antibodies for IFITM1, IFITM2/3, and FLAG, as well as corresponding isotypes. Cells were then analyzed by flow cytometry. Inhibition of IFITM1-transduced HTR8/SVneo cell invasion , quantified using IncuCyte technology (D–F) . HTR8/SVneo cells transduced with IFITM1–3 were cultured in a monolayer in 96-well plates and a wound was made using a 96-well wound maker; this was covered by Matrigel and cells were imaged with Incucyte every 30 min for 48 h. (D) Representative images of transduced HTR8/SVneo cell invasion at 48 h. The blue region denotes the area of the initial wound (light blue line) covered by advancing cells. (E) Time course of wound closure expressed as relative wound density (%). Values are reported as mean ± SEM of the percentage. (F) Comparison between cells transduced with IFITM1–3 and the empty vector was performed using an analysis of the area under the curve of the replicates represented in (E). Values are represented as mean + SEM (n = 6 wells/condition, n = 3 experiments). Statistical analysis was performed with one-way ANOVA to compare treatment to vehicle controls. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Ectopic expression of GFP , FLAG , and IFITMs in EVCT explants transduced with IFITM1–3 was verified by immunofluorescence (G–J) . (G) Representative image of placental explants transduced with GFP or IFITM1–3, cultured on Matrigel, and immunostained for FLAG (yellow), GFP (green), and IFITM1 (red) or IFITM2/3 (magenta), and then counterstained with DAPI (blue). Scale bars: 100 μm. (H) Representative image of EVCT explants transduced with GFP or IFITM1–3, cultured on Matrigel, and immunostained for FLAG (yellow), GFP (green), and ITGA5 (red) or HLAG (magenta), and then counterstained with DAPI (blue). Scale bars: 100 μm. Inhibition of IFITM1-transduced EVCT invasion using villous explant culture model (I–J) . (I) Representative image of transduced extravillous explants cultured on Matrigel and immunostained for integrin α5 (ITGA5, marker of invasion, red). Scale bars: 100 μm. (J) Statistical analysis of the invasion distance of ITGA5 + EVCTs, as representatively shown in I. Values are presented as mean + SD (n = 3 explants per condition, n = 3 placentas). One-way ANOVA was performed to compare treatment to pTRIP-GFP control; ∗∗∗∗p < 0.0001.

Article Snippet: Rabbit anti-IFITM1 polyclonal antibody , Sigma-Aldrich , Cat# HPA004810; RRID: AB_1851419.

Techniques: Expressing, Transduction, Western Blot, Immunofluorescence, Flow Cytometry, SDS Page, Plasmid Preparation, Staining, Inhibition, Cell Culture, Marker

Induction of IFITM1 expression in placental tissues from IFN-induced pathologies of pregnancy (A) Representative images of CK7, IFITM1, and HLAG immunostaining and HES staining in placental tissues from CMV- and bacterial-infected patients (left panel) and non-infected controls (right panel). Yellow asterisks represent EVCTs (CK7+, HLGA+). Scale bars: 200 μm. The insets depict a higher magnification of EVCT labeling. Scale bar: 20 μm. (B) Quantification of IFITM1 protein expression in EVCTs from CMV- and bacterial-infected and non-infected control pregnancies at three different weeks of gestation (19, 24, and 34 WG, n = 1 per condition, 25 non-overlapping ROIs per placenta). (C) Statistical analyses of IFITM1 protein expression of data shown in B combined by all gestational ages per (n = 3 placentas (19, 24, and 34 WG) per condition (CMV- or bacterial-infected and non-infected), 75 non-overlapping ROIs per condition). Values are presented as mean + SD. One-way ANOVA was performed to compare infected to non-infected controls; ∗∗∗∗p < 0.0001.

Journal: iScience

Article Title: IFITM1 inhibits trophoblast invasion and is induced in placentas associated with IFN-mediated pregnancy diseases

doi: 10.1016/j.isci.2023.107147

Figure Lengend Snippet: Induction of IFITM1 expression in placental tissues from IFN-induced pathologies of pregnancy (A) Representative images of CK7, IFITM1, and HLAG immunostaining and HES staining in placental tissues from CMV- and bacterial-infected patients (left panel) and non-infected controls (right panel). Yellow asterisks represent EVCTs (CK7+, HLGA+). Scale bars: 200 μm. The insets depict a higher magnification of EVCT labeling. Scale bar: 20 μm. (B) Quantification of IFITM1 protein expression in EVCTs from CMV- and bacterial-infected and non-infected control pregnancies at three different weeks of gestation (19, 24, and 34 WG, n = 1 per condition, 25 non-overlapping ROIs per placenta). (C) Statistical analyses of IFITM1 protein expression of data shown in B combined by all gestational ages per (n = 3 placentas (19, 24, and 34 WG) per condition (CMV- or bacterial-infected and non-infected), 75 non-overlapping ROIs per condition). Values are presented as mean + SD. One-way ANOVA was performed to compare infected to non-infected controls; ∗∗∗∗p < 0.0001.

Article Snippet: Rabbit anti-IFITM1 polyclonal antibody , Sigma-Aldrich , Cat# HPA004810; RRID: AB_1851419.

Techniques: Expressing, Immunostaining, Staining, Infection, Labeling

Journal: iScience

Article Title: IFITM1 inhibits trophoblast invasion and is induced in placentas associated with IFN-mediated pregnancy diseases

doi: 10.1016/j.isci.2023.107147

Figure Lengend Snippet:

Article Snippet: Rabbit anti-IFITM1 polyclonal antibody , Sigma-Aldrich , Cat# HPA004810; RRID: AB_1851419.

Techniques: Recombinant, Electron Microscopy, Selection, Bicinchoninic Acid Protein Assay, Plasmid Preparation, Software

Review

polyclonal rabbit anti ifitm1 antibody (Cell Signaling Technology Inc)

Structured Review

Images

Related Articles

other:

Western Blot:

Blocking Assay:

Similar Products

Image Search Results